Novartis Says FDA Approved Cholesterol Therapy
December 23 2021 - 2:26AM
Dow Jones News
By Cristina Roca
Novartis AG said late Wednesday that the U.S. Food and Drug
Administration has approved Leqvio, a cholesterol therapy.
The Swiss pharmaceutical major said the treatment is the first
and only small interfering RNA therapy to lower low-density
lipoprotein cholesterol--also known as bad cholesterol--with two
doses a year, delivered by injection.
"This approach may help those who have trouble sticking to
medicines that are self-administered and have greater dosing
frequency," the company said.
Leqvio will be available in early January, it said.
Novartis has acquired global rights to develop, manufacture and
commercialize the drug under an agreement with Alnylam
Pharmaceuticals Inc.
Write to Cristina Roca at cristina.roca@wsj.com
(END) Dow Jones Newswires
December 23, 2021 02:11 ET (07:11 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2023 to Apr 2024